Practice Update: Oncology

CONTENTS 5

COVER

RESEARCH Editor’s picks 6 Noninferiority of Partial-Breast and Reduced-Dose Radiotherapy After Breast Conservation Surgery for Patients With Early Breast Cancer Comment by Noam VanderWalde MD 7 The BRCA1ness Signature is Associated Significantly With Response to PARP Inhibitors in the I-SPY 2 Randomized Neoadjuvant Setting 8 Improved Efficacy of Palbociclib vs Chemotherapy for the Treatment of Postmenopausal Women With HR+/HER2− Advanced/Metastatic Breast Cancer Comment by Lee S. Schwartzberg MD, FACP 9 Neratinib Efficacy and ctDNA Detection of HER2 Mutations in HER2 Non-Amplified Metastatic Breast Cancer Comment by Reshma L. Mahtani DO 10 Effect of Interleukin-1β Inhibition With Canakinumab on Incident Lung Cancer in Patients With Atherosclerosis Comment by Peter Libby MD 11 Lenalidomide Maintenance After First-Line Therapy for High-Risk Chronic Lymphocytic Leukemia General oncology 26 Direct Detection of Early-Stage Cancers Using Circulating Tumor DNA Comment by Erin Schenk MD, PhD 27 Use of Alternative Medicine for Cancer Associated With Increased Mortality Breast 28 Adjuvant Tamoxifen and Exemestane in Women With Postmenopausal Early Breast Cancer Comment by Annette Hasenburg Prof. Dr. med 29 Ipatasertib Plus Paclitaxel vs Placebo Plus Paclitaxel as First-Line Therapy for Metastatic Triple-Negative Breast Cancer Comment by Lee S. Schwartzberg MD, FACP Hematology 30 Lenalidomide vs Placebo Maintenance After Single ASCT for Multiple Myeloma Comment by Rafael D. Fonseca MD 31 Novel Composite Model to Estimate Risk of Mortality in AML 31 Long-Term Follow-Up of Chemoimmunotherapy With Rituximab, Oxaliplatin, Cytosine Arabinoside, Dexamethasone in Patients With Relapsed CD20+ B-Cell NHL

10 Effect of Interleukin-1β Inhibition With Canakinumab on Incident Lung Cancer in Patients With Atherosclerosis

CONFERENCE 14

ESMO 2017 Congress

FEATURES – Q & A 32 Emerging Science in Gliomas and Glioblastomas: A Review 33 Current Concepts in Stem Cell Transplantation for Multiple Myeloma 34 New Data on Immunotherapy for Bladder Cancer: Part 1 14 Nutritional Status and Treatment Response: An Update 15 Abiraterone Acetate Plus Prednisolone Comparable to Docetaxel in High-Risk Prostate Cancer 16 New Data on Anti-Emesis Agents 16 Updates in the Management of GBM 17 New Data on the Management of HCC 20 MONARCH 3: Abemaciclib Improves Progression-Free Survival in Endocrine- Sensitive Advanced Breast Cancer 21 Systemic Immune-Inflammation Index, Neutrophil-Lymphocyte Ratio, and Platelet-Lymphocyte Ratio are Robust Predictors of Outcome of Nivolumab Therapy for Metastatic Renal Cell Carcinoma

22 Three Months of Oxaliplatin-Based Chemotherapy Usually Suffices, With Less Neurotoxicity Than 6 Months, in Stage 3 Colon Cancer 23 Cabozantinib Is Safe and Effective for Metastatic Renal Cell Carcinoma in Real- World Practice 24 MicroRNAs Are Identified as Possible Biomarkers of Outcome With Bevacizumab in Metastatic Breast Cancer

VOL. 1 • NO. 3 • 2017